Company: CERO
Filing Date: 2025-11-17
Form Type: PRE 14A
Source: 0001213900-25-111175
Chunk: 90

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-17
Form: PRE 14A
Chunk 90
---
exclusive, worldwide license to share the other party’s technologies to create bi -functionalT -cells. Legacy CERo was responsible for all employee and other internal costs incurred in the performance of all of Legacy CERo’s R&D activities, with approved cost overruns funded by the collaborative partner. At the end of the research project, the collaborative partner would be granted the option to enter into an exclusive license for the further development of the combined drug. Under the Collaboration Agreement, the collaborative partner paid us $0 for the year ended December 31, 2023. The Collaboration Agreement terminated on March 3, 2023. PIPE Financings In February 2024, we issued and sold an aggregate of 10,089 shares of Series A Preferred Stock, 306 Series A Warrants and 2,500 Preferred Warrants, at a price of $1,000 per share of Series A Preferred Stock, for aggregate cash proceeds of approximately $8.0 million, plus additional cash proceeds of up to $2.0 million if the Preferred Warrants are exercised. The following table summarizes the shares of our Series A Preferred Stock issued to our related parties:

| Purchasers(1)                          |     | Shares of 
  Series A 
 Preferred 
     Stock |     | Total    
 Purchase 
 Price    |           |
|:---------------------------------------|:----|----------:|:----|:---------|----------:|
| Daniel Corey(2)                        |     |       150 |     | $        |   150,000 |
| Atwood-Edminster Trust dtd 4-2-2000(3) |     |     1,002 |     | $        | 1,002,000 |
| Chris Ehrlich(4)                       |     |       275 |     | $        |   275,000 |
| Phoenix Biotech Sponsor, LLC(5)        |     |     1,380 |     | $        | 1,380,000 |

____________ (1)Additional details regarding these stockholders and their equity holdings are included in this proxy statement under the section “Security Ownership of Certain Beneficial Owners and Management.” (2)Daniel Corey served as the Chief Technology Officer and a member of the board of directors from February 2024 to September 2024, and previously served as Chief Executive Officer, Chief Scientific Officer, and a member of the board of directors of Legacy CERo until the closing of the Business Combination in February